The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia

Haematologica

Volumn 86, Issue 5, 2001, Pages 470-477

  Schaich, Markus ^a   Illmer, Thomas ^a   Seitz, Gabriele ^b   Mohr, Brigitte ^a   Schäkel, Ulrike ^a   Beck, James F ^b   Ehninger, Gerhard ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NONE

Author keywords

AML; Bax; Bcl 2; Bcl XL; Mdr1; Treatment response

Indexed keywords

BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BIOLOGICAL MARKER; MESSENGER RNA; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; PROGNOSIS; REMISSION;

ACUTE DISEASE; ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BIOLOGICAL MARKERS; CYTOGENETIC ANALYSIS; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; RNA, MESSENGER;

EID: 0035348134     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34:9-19.
2. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-XL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996; 56:4743-8.
3. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47:19-28.
4. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83:5214-8.
5. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091-6.
6. Maung ZT, MacLean FR, Reid MM, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994; 88:105-9.
7. Filipits M, Stranzl T, Pohl G, et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 2000; 14:68-76.
8. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999; 13:1943-53.
9. Kohler T, Leiblein S, Borchert S, et al. Absolute levels of MDR-1, MRP, and BCL-2 mRNA and tumor remission in acute leukemia. Adv Exp Med Biol 1999; 457:177-85.
10. Bincoletto C, Saad ST, da Silva ES, Queiroz ML. Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia. Eur J Haematol 1999; 62:38-42.
11. Naumovski L, Martinovsky G, Wong C, et al. BCL-2 expression does not not correlate with patient outcome in pediatric acute myelogenous leukemia. Leuk Res 1998; 22:81-7.
12. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997; 11:2075-8.
13. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9:159-65.
14. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91:391-1000.
15. Stoetzer OJ, Nussler V, Darsow M, et al. Association of bcl-2, bax, bcl-xL and interleukin-1 β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996; 10 (Suppl3):S18-S22.
16. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94:1086-99.
17. Beck J, Handgretinger R, Klingebiel T, et al. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML Leukemia 1996; 10:426-33.
18. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173-9.
19. Kornblau SM, Thall PF, Estrov Z, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999; 5:1758-66.
20. Schaich M, Ritter M, Illmer T, et al. Mutations in ras proto-oncogenes are associated with lower MDR1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001; 112:300-7.
21. Rowley JD, Aster JC, Sklar J. The clinical applications of new DNA diagnostic technology on the management of cancer patients. JAMA 1993; 270:2331-7.
22. Gramatzki M, Ludwig WD, Burger R, et al. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 1998; 26:1209-14.
23. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998; 91:22-9.
24. Cascavilla N, Melillo L, D'Arena G, et al. Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases. Leuk Lymphoma 2000; 37:105-13.
25. Pallis M, Zhu YM, Russell NH. Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 1997; 11:945-9.
26. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999; 93:2671-8.
27. Kornblau SM, Vu HT, Ruvolo P, et al. BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000; 6:1401-9.